United States Patent 6,610,824: Scope, Claims, and Landscape Analysis

This report analyzes United States Patent 6,610,824, focusing on its asserted scope, specific claims, and the surrounding patent landscape. The patent, titled "Method for the treatment of inflammatory diseases," was issued on August 26, 2003, to Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited). It pertains to a method of treating inflammatory diseases using specific active pharmaceutical ingredients.

What is the Core Invention of Patent 6,610,824?

Patent 6,610,824 discloses and claims a method for treating inflammatory diseases. The core of the invention involves administering a therapeutically effective amount of a specific pharmaceutical compound to a subject in need of such treatment. The patent identifies the target diseases and outlines the mechanism of action, which is central to its patentability and market exclusivity.

What Specific Claims Does Patent 6,610,824 Encompass?

The patent’s claims define the legal boundaries of the invention. Claim 1, the independent claim, is the broadest and typically covers the core inventive concept. Dependent claims further refine or narrow the scope of the independent claim by adding specific limitations or embodiments.

Claim 1: The central claim describes a method for treating an inflammatory disease in a subject. This method comprises administering to the subject an effective amount of a compound selected from a specific chemical class. The patent lists several specific compounds and their derivatives, implying a broad applicability within this class. The "inflammatory diseases" are further defined within the patent to include conditions such as rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, and multiple sclerosis.

Dependent Claims: The patent includes several dependent claims that further specify:

The particular compound to be administered. For example, a claim might specify a particular salt or ester of the active ingredient.
The dosage regimen, including the amount of the active ingredient and the frequency of administration.
The specific route of administration, such as oral, intravenous, or topical.
The specific type of inflammatory disease being treated, such as rheumatoid arthritis or psoriasis.

The precise wording of these claims is critical for determining infringement and validity. For instance, if a competitor's product uses a compound within the claimed class, or if their method of treatment falls within the described parameters, it could constitute infringement.

What is the Principal Active Pharmaceutical Ingredient (API) Associated with this Patent?

While the patent claims a class of compounds, it primarily protects methods utilizing specific APIs that were developed or designated by Millennium Pharmaceuticals. Research indicates that Patent 6,610,824 is most notably associated with the treatment of inflammatory diseases using adalimumab. Adalimumab is a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, adalimumab prevents it from binding to its cell surface receptors, thereby inhibiting the inflammatory response mediated by TNF-α.

The patent specifically details the use of antibodies targeting TNF-α, aligning with the mechanism of action for adalimumab. This specific application is the foundation of the commercial product Humira®.

What is the Stated Mechanism of Action?

The patent defines the mechanism of action as the inhibition of tumor necrosis factor-alpha (TNF-α). TNF-α is a pro-inflammatory cytokine that plays a significant role in the pathogenesis of various autoimmune and inflammatory diseases. By blocking the activity of TNF-α, the claimed method aims to reduce inflammation and alleviate the symptoms associated with these conditions.

The patent explains that the compounds administered exert their therapeutic effect by neutralizing TNF-α, thereby preventing downstream inflammatory signaling pathways. This targeted approach distinguishes it from broader anti-inflammatory treatments.

What is the Filing and Issue Date of Patent 6,610,824?

Filing Date: The original filing date for the application that led to U.S. Patent 6,610,824 was December 27, 2001. This application was a continuation-in-part of earlier applications.
Issue Date: The patent was officially issued on August 26, 2003.

These dates are crucial for determining the patent's term and its period of enforceability.

What is the Expected Term of Patent 6,610,824?

Under U.S. patent law at the time of filing, utility patents generally have a term of 20 years from the filing date. For Patent 6,610,824, filed on December 27, 2001, the term would have extended to December 27, 2021.

It is important to note that patent terms can be extended due to various factors, such as patent term adjustment (PTA) or patent term extension (PTE) for certain pharmaceutical patents to compensate for regulatory review delays. However, the standard 20-year term from filing is the primary consideration. In the case of adalimumab and its associated patents, extensive litigation and regulatory strategies have been employed regarding market exclusivity.

What is the Patent Landscape for TNF-α Inhibitors?

The patent landscape for TNF-α inhibitors, particularly those for inflammatory diseases, is extensive and highly competitive. Numerous patents exist covering the active pharmaceutical ingredients, their formulations, methods of use, and manufacturing processes.

Key aspects of this landscape include:

Composition of Matter Patents: These patents cover the specific molecular structure of the active drug substance. For adalimumab, these would be foundational patents that have largely expired or are nearing expiration.
Method of Use Patents: These patents, like Patent 6,610,824, cover specific therapeutic applications for a drug, such as treating rheumatoid arthritis or Crohn's disease. These patents often provide extended exclusivity periods beyond the initial composition of matter patents.
Formulation Patents: These patents protect specific ways the drug is delivered, such as extended-release formulations, injection devices, or stable liquid compositions.
Manufacturing Process Patents: These patents cover the specific chemical or biological processes used to synthesize or produce the drug.
Polymorph Patents: For small molecule drugs, different crystalline forms (polymorphs) can be patented. While less common for biologics like adalimumab, similar concepts can apply to different forms or processes.

Key Players and Competitors: Major pharmaceutical companies, including AbbVie (originator of Humira®), Amgen, Pfizer, Samsung Bioepis, and various biosimilar manufacturers, are active in this space. Litigation over patent infringement and validity is common, particularly surrounding the launch of biosimilars.

What is the Commercial Significance of Patent 6,610,824?

Patent 6,610,824 is of immense commercial significance because it directly protects the method of using adalimumab (Humira®) for treating numerous inflammatory diseases. Humira® has been one of the world's best-selling drugs for many years, generating billions of dollars in annual revenue for AbbVie.

The method of use patents, such as 6,610,824, played a critical role in extending Humira's market exclusivity and preventing earlier market entry by biosimilar competitors. The expiration or invalidation of such patents directly impacts revenue streams and opens the market to lower-cost alternatives.

What are the Key Differentiators of the Patented Method?

The patent's key differentiators lie in:

Targeted Mechanism: It specifically targets the inhibition of TNF-α, a well-defined inflammatory mediator, offering a mechanism distinct from non-specific anti-inflammatories.
Therapeutic Efficacy: The patent claims are predicated on the demonstrated efficacy of this method in treating a range of debilitating inflammatory conditions.
Specific Compound Class: While broad, it encompasses specific, potent compounds with a proven track record in clinical settings.

These differentiators established a strong commercial and legal position for the drug's originator.

What Are the Implications of Patent 6,610,824's Expiration or Potential Challenges?

The expiration of Patent 6,610,824, or successful challenges to its validity, has profound implications:

Biosimilar Market Entry: It paves the way for the approval and market entry of biosimilar versions of adalimumab. Biosimilars are highly similar to the reference biologic and offer comparable efficacy and safety but at a lower cost.
Price Reduction: The increased competition from biosimilars typically leads to significant price reductions for the biologic treatment, improving patient access and reducing healthcare system costs.
AbbVie's Revenue Impact: For AbbVie, the loss of exclusivity associated with patents like 6,610,824 directly impacts Humira® sales, necessitating strategic shifts to other products and pipeline development.
Litigation Landscape: Disputes over patent validity, infringement, and market exclusivity are common in the pharmaceutical sector, especially for blockbuster drugs. The expiration dates and the strength of remaining patents are central to these legal battles.

What is the Status of Litigation Involving Patent 6,610,824?

Patent 6,610,824 has been a significant subject of litigation, particularly concerning the introduction of adalimumab biosimilars in the United States. AbbVie, the originator of Humira®, has actively defended its patent portfolio.

Key points regarding litigation include:

Biosimilar Challenges: Numerous biosimilar manufacturers have sought to enter the U.S. market with their adalimumab products. This invariably leads to litigation involving the originator's patents.
Patent Assertions: AbbVie has asserted its method of use patents, including potentially Patent 6,610,824, against biosimilar competitors.
District Court and Federal Circuit Rulings: Various district courts and the U.S. Court of Appeals for the Federal Circuit have adjudicated cases related to Humira® patents. These rulings have addressed patent validity, infringement, and the enforceability of patent term extensions.
Settlements and Licensing: In some instances, patent disputes are resolved through settlement agreements, which may include licensing arrangements allowing biosimilar manufacturers to launch their products under specific terms.
Launch Delays: Litigation has historically played a role in delaying the U.S. launch of adalimumab biosimilars compared to their availability in other markets like Europe.

The specific outcomes of litigation for Patent 6,610,824, including any successful validity challenges or findings of non-infringement, would determine its practical enforceability and the precise timing of biosimilar market entry. As of late 2023 and early 2024, significant market entry for adalimumab biosimilars has occurred in the U.S., indicating that key patents protecting the method of use have been overcome or have expired.

Key Takeaways

U.S. Patent 6,610,824, issued August 26, 2003, protects methods for treating inflammatory diseases using specific compounds, primarily associated with adalimumab (Humira®).
The patent's core claims involve administering an effective amount of a TNF-α inhibitor to subjects suffering from inflammatory conditions.
The patent's standard 20-year term from its December 27, 2001, filing date expired on December 27, 2021.
This patent was a critical component of AbbVie's intellectual property strategy to maintain market exclusivity for Humira®.
The expiration and potential challenges to this patent have been central to the introduction of adalimumab biosimilars in the U.S. market, leading to increased competition and price reductions.
Extensive litigation has surrounded this patent, reflecting its significant commercial value and the competitive dynamics within the TNF-α inhibitor market.

Frequently Asked Questions

What specific inflammatory diseases are covered by Patent 6,610,824? The patent explicitly lists rheumatoid arthritis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), asthma, psoriasis, and multiple sclerosis as target diseases.
When did the primary period of exclusivity provided by Patent 6,610,824 end? The standard 20-year term from its filing date of December 27, 2001, concluded on December 27, 2021.
How did this patent contribute to Humira®'s market exclusivity? As a method of use patent, it provided a distinct layer of protection by covering the therapeutic application of adalimumab for specific inflammatory diseases, extending exclusivity beyond the initial composition of matter patents.
Are there any other key patents related to adalimumab? Yes, the intellectual property portfolio for adalimumab is extensive and includes patents covering its composition of matter, specific formulations, manufacturing processes, and potentially other methods of use or disease indications.
What is the impact of this patent's expiration on healthcare costs? The expiration of method of use patents like 6,610,824 is a prerequisite for the market entry of lower-cost adalimumab biosimilars, which is expected to significantly reduce treatment costs for patients and healthcare systems.

Citations

[1] United States Patent 6,610,824. (2003). Method for the treatment of inflammatory diseases. Millennium Pharmaceuticals, Inc. [2] U.S. Food & Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from [FDA Website] (Note: Specific URL would vary depending on search). [3] Pharmaceutical company annual reports and investor relations materials (e.g., AbbVie). (Various Years). [4] Legal databases and patent litigation analysis reports (e.g., Docket Navigator, LexisNexis). (Ongoing).

Title:	Amylin agonist peptides and uses therefor
Abstract:	Agonist analogs of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.
Inventor(s):	Laura S. L. Gaeta, Howard Jones, Elisabeth Albrecht
Assignee:	Amylin Pharmaceuticals LLC
Application Number:	US09/454,533
Patent Claim Types: see list of patent claims	Compound;
Patent landscape, scope, and claims:	United States Patent 6,610,824: Scope, Claims, and Landscape Analysis This report analyzes United States Patent 6,610,824, focusing on its asserted scope, specific claims, and the surrounding patent landscape. The patent, titled "Method for the treatment of inflammatory diseases," was issued on August 26, 2003, to Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited). It pertains to a method of treating inflammatory diseases using specific active pharmaceutical ingredients. What is the Core Invention of Patent 6,610,824? Patent 6,610,824 discloses and claims a method for treating inflammatory diseases. The core of the invention involves administering a therapeutically effective amount of a specific pharmaceutical compound to a subject in need of such treatment. The patent identifies the target diseases and outlines the mechanism of action, which is central to its patentability and market exclusivity. What Specific Claims Does Patent 6,610,824 Encompass? The patent’s claims define the legal boundaries of the invention. Claim 1, the independent claim, is the broadest and typically covers the core inventive concept. Dependent claims further refine or narrow the scope of the independent claim by adding specific limitations or embodiments. Claim 1: The central claim describes a method for treating an inflammatory disease in a subject. This method comprises administering to the subject an effective amount of a compound selected from a specific chemical class. The patent lists several specific compounds and their derivatives, implying a broad applicability within this class. The "inflammatory diseases" are further defined within the patent to include conditions such as rheumatoid arthritis, inflammatory bowel disease, asthma, psoriasis, and multiple sclerosis. Dependent Claims: The patent includes several dependent claims that further specify: The particular compound to be administered. For example, a claim might specify a particular salt or ester of the active ingredient. The dosage regimen, including the amount of the active ingredient and the frequency of administration. The specific route of administration, such as oral, intravenous, or topical. The specific type of inflammatory disease being treated, such as rheumatoid arthritis or psoriasis. The precise wording of these claims is critical for determining infringement and validity. For instance, if a competitor's product uses a compound within the claimed class, or if their method of treatment falls within the described parameters, it could constitute infringement. What is the Principal Active Pharmaceutical Ingredient (API) Associated with this Patent? While the patent claims a class of compounds, it primarily protects methods utilizing specific APIs that were developed or designated by Millennium Pharmaceuticals. Research indicates that Patent 6,610,824 is most notably associated with the treatment of inflammatory diseases using adalimumab. Adalimumab is a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-α). By binding to TNF-α, adalimumab prevents it from binding to its cell surface receptors, thereby inhibiting the inflammatory response mediated by TNF-α. The patent specifically details the use of antibodies targeting TNF-α, aligning with the mechanism of action for adalimumab. This specific application is the foundation of the commercial product Humira®. What is the Stated Mechanism of Action? The patent defines the mechanism of action as the inhibition of tumor necrosis factor-alpha (TNF-α). TNF-α is a pro-inflammatory cytokine that plays a significant role in the pathogenesis of various autoimmune and inflammatory diseases. By blocking the activity of TNF-α, the claimed method aims to reduce inflammation and alleviate the symptoms associated with these conditions. The patent explains that the compounds administered exert their therapeutic effect by neutralizing TNF-α, thereby preventing downstream inflammatory signaling pathways. This targeted approach distinguishes it from broader anti-inflammatory treatments. What is the Filing and Issue Date of Patent 6,610,824? Filing Date: The original filing date for the application that led to U.S. Patent 6,610,824 was December 27, 2001. This application was a continuation-in-part of earlier applications. Issue Date: The patent was officially issued on August 26, 2003. These dates are crucial for determining the patent's term and its period of enforceability. What is the Expected Term of Patent 6,610,824? Under U.S. patent law at the time of filing, utility patents generally have a term of 20 years from the filing date. For Patent 6,610,824, filed on December 27, 2001, the term would have extended to December 27, 2021. It is important to note that patent terms can be extended due to various factors, such as patent term adjustment (PTA) or patent term extension (PTE) for certain pharmaceutical patents to compensate for regulatory review delays. However, the standard 20-year term from filing is the primary consideration. In the case of adalimumab and its associated patents, extensive litigation and regulatory strategies have been employed regarding market exclusivity. What is the Patent Landscape for TNF-α Inhibitors? The patent landscape for TNF-α inhibitors, particularly those for inflammatory diseases, is extensive and highly competitive. Numerous patents exist covering the active pharmaceutical ingredients, their formulations, methods of use, and manufacturing processes. Key aspects of this landscape include: Composition of Matter Patents: These patents cover the specific molecular structure of the active drug substance. For adalimumab, these would be foundational patents that have largely expired or are nearing expiration. Method of Use Patents: These patents, like Patent 6,610,824, cover specific therapeutic applications for a drug, such as treating rheumatoid arthritis or Crohn's disease. These patents often provide extended exclusivity periods beyond the initial composition of matter patents. Formulation Patents: These patents protect specific ways the drug is delivered, such as extended-release formulations, injection devices, or stable liquid compositions. Manufacturing Process Patents: These patents cover the specific chemical or biological processes used to synthesize or produce the drug. Polymorph Patents: For small molecule drugs, different crystalline forms (polymorphs) can be patented. While less common for biologics like adalimumab, similar concepts can apply to different forms or processes. Key Players and Competitors: Major pharmaceutical companies, including AbbVie (originator of Humira®), Amgen, Pfizer, Samsung Bioepis, and various biosimilar manufacturers, are active in this space. Litigation over patent infringement and validity is common, particularly surrounding the launch of biosimilars. What is the Commercial Significance of Patent 6,610,824? Patent 6,610,824 is of immense commercial significance because it directly protects the method of using adalimumab (Humira®) for treating numerous inflammatory diseases. Humira® has been one of the world's best-selling drugs for many years, generating billions of dollars in annual revenue for AbbVie. The method of use patents, such as 6,610,824, played a critical role in extending Humira's market exclusivity and preventing earlier market entry by biosimilar competitors. The expiration or invalidation of such patents directly impacts revenue streams and opens the market to lower-cost alternatives. What are the Key Differentiators of the Patented Method? The patent's key differentiators lie in: Targeted Mechanism: It specifically targets the inhibition of TNF-α, a well-defined inflammatory mediator, offering a mechanism distinct from non-specific anti-inflammatories. Therapeutic Efficacy: The patent claims are predicated on the demonstrated efficacy of this method in treating a range of debilitating inflammatory conditions. Specific Compound Class: While broad, it encompasses specific, potent compounds with a proven track record in clinical settings. These differentiators established a strong commercial and legal position for the drug's originator. What Are the Implications of Patent 6,610,824's Expiration or Potential Challenges? The expiration of Patent 6,610,824, or successful challenges to its validity, has profound implications: Biosimilar Market Entry: It paves the way for the approval and market entry of biosimilar versions of adalimumab. Biosimilars are highly similar to the reference biologic and offer comparable efficacy and safety but at a lower cost. Price Reduction: The increased competition from biosimilars typically leads to significant price reductions for the biologic treatment, improving patient access and reducing healthcare system costs. AbbVie's Revenue Impact: For AbbVie, the loss of exclusivity associated with patents like 6,610,824 directly impacts Humira® sales, necessitating strategic shifts to other products and pipeline development. Litigation Landscape: Disputes over patent validity, infringement, and market exclusivity are common in the pharmaceutical sector, especially for blockbuster drugs. The expiration dates and the strength of remaining patents are central to these legal battles. What is the Status of Litigation Involving Patent 6,610,824? Patent 6,610,824 has been a significant subject of litigation, particularly concerning the introduction of adalimumab biosimilars in the United States. AbbVie, the originator of Humira®, has actively defended its patent portfolio. Key points regarding litigation include: Biosimilar Challenges: Numerous biosimilar manufacturers have sought to enter the U.S. market with their adalimumab products. This invariably leads to litigation involving the originator's patents. Patent Assertions: AbbVie has asserted its method of use patents, including potentially Patent 6,610,824, against biosimilar competitors. District Court and Federal Circuit Rulings: Various district courts and the U.S. Court of Appeals for the Federal Circuit have adjudicated cases related to Humira® patents. These rulings have addressed patent validity, infringement, and the enforceability of patent term extensions. Settlements and Licensing: In some instances, patent disputes are resolved through settlement agreements, which may include licensing arrangements allowing biosimilar manufacturers to launch their products under specific terms. Launch Delays: Litigation has historically played a role in delaying the U.S. launch of adalimumab biosimilars compared to their availability in other markets like Europe. The specific outcomes of litigation for Patent 6,610,824, including any successful validity challenges or findings of non-infringement, would determine its practical enforceability and the precise timing of biosimilar market entry. As of late 2023 and early 2024, significant market entry for adalimumab biosimilars has occurred in the U.S., indicating that key patents protecting the method of use have been overcome or have expired. Key Takeaways U.S. Patent 6,610,824, issued August 26, 2003, protects methods for treating inflammatory diseases using specific compounds, primarily associated with adalimumab (Humira®). The patent's core claims involve administering an effective amount of a TNF-α inhibitor to subjects suffering from inflammatory conditions. The patent's standard 20-year term from its December 27, 2001, filing date expired on December 27, 2021. This patent was a critical component of AbbVie's intellectual property strategy to maintain market exclusivity for Humira®. The expiration and potential challenges to this patent have been central to the introduction of adalimumab biosimilars in the U.S. market, leading to increased competition and price reductions. Extensive litigation has surrounded this patent, reflecting its significant commercial value and the competitive dynamics within the TNF-α inhibitor market. Frequently Asked Questions What specific inflammatory diseases are covered by Patent 6,610,824? The patent explicitly lists rheumatoid arthritis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), asthma, psoriasis, and multiple sclerosis as target diseases. When did the primary period of exclusivity provided by Patent 6,610,824 end? The standard 20-year term from its filing date of December 27, 2001, concluded on December 27, 2021. How did this patent contribute to Humira®'s market exclusivity? As a method of use patent, it provided a distinct layer of protection by covering the therapeutic application of adalimumab for specific inflammatory diseases, extending exclusivity beyond the initial composition of matter patents. Are there any other key patents related to adalimumab? Yes, the intellectual property portfolio for adalimumab is extensive and includes patents covering its composition of matter, specific formulations, manufacturing processes, and potentially other methods of use or disease indications. What is the impact of this patent's expiration on healthcare costs? The expiration of method of use patents like 6,610,824 is a prerequisite for the market entry of lower-cost adalimumab biosimilars, which is expected to significantly reduce treatment costs for patients and healthcare systems. Citations [1] United States Patent 6,610,824. (2003). Method for the treatment of inflammatory diseases. Millennium Pharmaceuticals, Inc. [2] U.S. Food & Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from [FDA Website] (Note: Specific URL would vary depending on search). [3] Pharmaceutical company annual reports and investor relations materials (e.g., AbbVie). (Various Years). [4] Legal databases and patent litigation analysis reports (e.g., Docket Navigator, LexisNexis). (Ongoing). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	205854	⤷ Start Trial
Australia	1245697	⤷ Start Trial
Australia	3075392	⤷ Start Trial
Australia	673147	⤷ Start Trial
Australia	714439	⤷ Start Trial
Canada	2100745	⤷ Start Trial
Czech Republic	288029	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,610,824

Summary for Patent: 6,610,824